It is also consistent with a small clinical trial study of the GLP-1RA drug exenatide, which significantly reduced heavy drinking days and total alcohol intake in patients with obesity12 and with a register-based study in Demark showing that GLP-1RAs (though semaglutide was not included) compared with dipeptidyl peptidase 4 inhibitors (DPP4) were associated with lower incidence of alcohol-related events in 2009–201713. The gene discussed is DPP4; the disease is alcohol drinking.